The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
How long pregnant women with Sickle Cell Disease (SCD) were exposed to Hydroxyurea.
Timeframe: Through completion of pregnancy, an average of 2 years
Dose of hydroxyurea taken during pregnancy.
Timeframe: Through completion of pregnancy, an average of 2 years
How long infants were exposed to Hydroxyurea.
Timeframe: Through study completion, an average of 2 years
Dose of hydroxyurea exposure in infants.
Timeframe: Through study completion, an average of 2 years
Health outcomes of infants exposed to Hydroxyurea.
Timeframe: Through study completion, an average of 2 years
Pregnancy in Sickle Cell Disease (SCD).
Timeframe: Start of pregnancy until June 2019
Comparative analysis of congenital malformations or medical conditions in infants
Timeframe: Through study completion, an average of 2 years